Clinical Trial Update: Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating adding anlotinib to whole-brain radiotherapy in small cell lung cancer patients with brain metastases; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Whole-Brain Radiotherapy | Phase 3 | Status: RECRUITING